Literature DB >> 27260611

General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.

Amanda J Leach1, Christine Wigger2, Jemima Beissbarth2, Donna Woltring2, Ross Andrews2, Mark D Chatfield2, Heidi Smith-Vaughan2, Peter S Morris2.   

Abstract

OBJECTIVES: This study aims to monitor the prevalence of suppurative otitis media in remote Indigenous communities after introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in October 2011. We previously reported a decline in suppurative OM following replacement of PCV7 by 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) in October 2009.
METHODS: We continued regular surveillance in remote Indigenous communities between February 2010 and August 2013. This analysis reports the general health, otitis media (OM), nasopharyngeal (NP) carriage and middle ear microbiology in children less than 36 months of age who received a primary course of at least two doses of PHiD-CV10 or PCV13, and not more than one dose of another pneumococcal vaccine.
RESULTS: Mean ages of 511 PHiD-CV10- and 140 PCV13-vaccinated children were 19 and 13 months, respectively. Most children received 3-dose non-mixed PCV schedules. At the time of assessment, general health was poor and prevalence of risk factors was high in both groups: overall, around 14% of children had scabies, 20% had impetigo, 59% had runny nose and 39% had cough. Average household size was 8 persons, and 60% of the mothers smoked. Bilaterally normal middle ears were detected in 10% and 7%, respectively. OM with effusion (OME), almost all bilateral, was diagnosed in 52% and 50%, any suppurative OM (acute OM or any tympanic membrane perforation [TMP]) in 37% and 41%, and TMP in 14% and 12%, respectively. Children in the PCV13 group had significantly less NP carriage of combined Streptococcus pneumoniae (Spn) and non-typeable Haemophilus influenzae (NTHi) (62% versus 51%) but significantly more polymicrobial (Spn and NTHi) middle ear cultures (12% versus 43%), and significantly less Staphylococcus aureus-positive middle ears (40% versus 7%). Although NP carriage of pneumococcal serotype 19A was low in the PCV13 group, serotypes 19F and 23F persist.
CONCLUSIONS: The general health, particularly ear health, of little children in remote Australian Indigenous communities remains in crisis. In particular, transition to PCV13 did not show substantial further improvement in ear health. Possible vaccine-related differences in microbiology, including potential beneficial effects of PHiD-CV10 on NTHi infection, need to be further evaluated in randomised trials.
Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Middle ear microbiology; Nasopharyngeal carriage; Non-typeable Haemophilus influenzae; Otitis media; Pneumococcal conjugate vaccines; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2016        PMID: 27260611     DOI: 10.1016/j.ijporl.2016.05.011

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  29 in total

1.  Panel 6: Otitis media and associated hearing loss among disadvantaged populations and low to middle-income countries.

Authors:  Amanda Jane Leach; Preben Homøe; Clemence Chidziva; Hasantha Gunasekera; Kelvin Kong; Mahmood F Bhutta; Ramon Jensen; Sharon Ovnat Tamir; Sumon Kumar Das; Peter Morris
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2020-01-21       Impact factor: 1.675

Review 2.  Panel 8: Vaccines and immunology.

Authors:  Mark R Alderson; Tim Murphy; Stephen I Pelton; Laura A Novotny; Laura L Hammitt; Arwa Kurabi; Jian-Dong Li; Ruth B Thornton; Lea-Ann S Kirkham
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-12-18       Impact factor: 1.675

3.  Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

Authors:  Amanda Jane Leach; Edward Kim Mulholland; Mathuram Santosham; Paul John Torzillo; Peter McIntyre; Heidi Smith-Vaughan; Nicole Wilson; Beth Arrowsmith; Jemima Beissbarth; Mark D Chatfield; Victor M Oguoma; Peter Stanley Morris
Journal:  BMC Pediatr       Date:  2021-03-08       Impact factor: 2.125

Review 4.  Streptococcus pneumoniae Otitis Media Pathogenesis and How It Informs Our Understanding of Vaccine Strategies.

Authors:  Caroline Bergenfelz; Anders P Hakansson
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-05-20

Review 5.  Recurrent Acute Otitis Media: What Are the Options for Treatment and Prevention?

Authors:  Anna Granath
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-05-09

6.  Upper airway viruses and bacteria in urban Aboriginal and Torres Strait Islander children in Brisbane, Australia: a cross-sectional study.

Authors:  Kerry-Ann F O'Grady; Kerry K Hall; Theo P Sloots; Jennie Anderson; Anne B Chang
Journal:  BMC Infect Dis       Date:  2017-04-04       Impact factor: 3.090

7.  Recommendations for application of Haemophilus influenzae PCR diagnostics to respiratory specimens for children living in northern Australia: a retrospective re-analysis.

Authors:  Jemima Beissbarth; Michael J Binks; Robyn L Marsh; Anne B Chang; Amanda J Leach; Heidi C Smith-Vaughan
Journal:  BMC Res Notes       Date:  2018-05-21

8.  A community-based service enhancement model of training and employing Ear Health Facilitators to address the crisis in ear and hearing health of Aboriginal children in the Northern Territory, the Hearing for Learning Initiative (the HfLI): study protocol for a stepped-wedge cluster randomised trial.

Authors:  Kelvin Kong; Alan Cass; Amanda Jane Leach; Peter Stanley Morris; Amy Kimber; Jiunn-Yih Su; Victor Maduabuchi Oguoma
Journal:  Trials       Date:  2021-06-16       Impact factor: 2.279

9.  Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.

Authors:  Xiao Jun Wang; Ashwini Saha; Xu-Hao Zhang
Journal:  Cost Eff Resour Alloc       Date:  2017-08-22

10.  A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.

Authors:  Lijoy Varghese; Louise Talbot; Andrea Govender; Xu-Hao Zhang; Bruce A Mungall
Journal:  Appl Health Econ Health Policy       Date:  2018-06       Impact factor: 2.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.